Vaginal cytokines do not correlate with XXXX .

@entity1 @entity172 @entity225 @entity2841 @entity4047 @entity5737 @entity146 @entity310 @entity1109 @entity3646 @entity688 @entity365 @entity10557
UNASSIGNED: Abstract Objectives: Exploratory pilot study to determine the correlation between @entity1109 and vaginal cytokine levels. Methods: Postmenopausal @entity1 (n   =   34) not using menopausal hormone therapy and presenting with or without symptoms of @entity146 were screened. Each @entity1 underwent a vaginal examination and screening for @entity365 . A cervicovaginal lavage (CVL) with sterile saline and a peripheral blood sample were obtained. Main outcome measures were assessed by Luminex   X-map method on the Bio-Plex   platform. Main outcome measures were cervicovaginal and serum @entity3646 , @entity225 , @entity688 , IL-12, @entity4047 , @entity310 , @entity2841 , @entity10557 and @entity5737 level. Cervicovaginale cytokines were adjusted to total protein concentration [pg/mcg protein]. Results: Twenty-six postmenopausal @entity1 were enrolled (symptomatic: n   =   15; asymptomatic: n   =   11). There were no significant differences between groups: age, age at menopause, vaginal pH and all CVL and serum cytokines ( @entity3646 , @entity225 , @entity688 , IL-12, @entity4047 , @entity310 , @entity2841 , @entity10557 and @entity5737 ). @entity2841 was the most abundant vaginal cytokine (symptomatic: 146.5        165.6   pg/mcg protein; asymptomatic: 146.0        173.5   pg/mcg protein; p   =   0.99). Conclusions: Postmenopausal vulvovaginal symptoms did not correlate with vaginal inflammatory marker. There was no difference in serum or CVL cytokines between symptomatic and asymptomatic postmenopasual @entity1 . Vaginal symptoms after menopause are not related to the vaginal cytokine changes associated with loss of @entity172 .
